LA JOLLA, Calif., Oct. 28, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (OTCQB:KURO), a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, today announced that it has commenced an underwritten public offering of shares of its common stock and expects to raise gross proceeds of approximately $60 million. In addition, Kura will grant the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering on the same terms and conditions to cover over-allotments, if any. Kura, which is currently listed on the OTCQB® Venture Marketplace, has applied to list its shares on The Nasdaq Global Select Market under the symbol “KURA”.
Citigroup and Leerink Partners are acting as joint book-running managers for the proposed offering. JMP Securities and Oppenheimer & Co. are acting as co-lead managers for the offering.
A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. The offering is being made only by means of a prospectus forming part of the effective registration statement. A copy of the final prospectus relating to these securities will be filed with the SEC and may be obtained, when available, from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at prospectus@citi.com or by phone at (800) 831-9146 or from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by email at syndicate@leerink.com or by phone at (800) 808-7525, ext. 6142.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for the treatment of solid tumors and blood cancers. Kura’s pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. The company’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor that is currently in two Phase 2 clinical studies: the first in patients with locally advanced tumors that carry HRAS mutations and the second in patients with peripheral T-cell lymphoma. The company’s preclinical pipeline includes KO-947, an ERK inhibitor, and a menin-MLL inhibitor program.
CONTACT: INVESTOR CONTACT: Robert H. Uhl Managing Director Westwicke Partners, LLC (858) 356-5932 robert.uhl@westwicke.com MEDIA CONTACT: Mark Corbae Vice President Canale Communications (619) 849 5375 mark@canalecomm.com
Help employers find you! Check out all the jobs and post your resume.
